1. Home
  2. RCUS vs SDGR Comparison

RCUS vs SDGR Comparison

Compare RCUS & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • SDGR
  • Stock Information
  • Founded
  • RCUS 2015
  • SDGR 1990
  • Country
  • RCUS United States
  • SDGR United States
  • Employees
  • RCUS N/A
  • SDGR N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • SDGR Biotechnology: Pharmaceutical Preparations
  • Sector
  • RCUS Health Care
  • SDGR Health Care
  • Exchange
  • RCUS Nasdaq
  • SDGR Nasdaq
  • Market Cap
  • RCUS 1.2B
  • SDGR 1.4B
  • IPO Year
  • RCUS 2018
  • SDGR 2020
  • Fundamental
  • Price
  • RCUS $13.90
  • SDGR $20.15
  • Analyst Decision
  • RCUS Buy
  • SDGR Buy
  • Analyst Count
  • RCUS 7
  • SDGR 8
  • Target Price
  • RCUS $22.00
  • SDGR $27.25
  • AVG Volume (30 Days)
  • RCUS 937.9K
  • SDGR 1.1M
  • Earning Date
  • RCUS 11-05-2025
  • SDGR 11-11-2025
  • Dividend Yield
  • RCUS N/A
  • SDGR N/A
  • EPS Growth
  • RCUS N/A
  • SDGR N/A
  • EPS
  • RCUS N/A
  • SDGR N/A
  • Revenue
  • RCUS $262,000,000.00
  • SDGR $237,917,000.00
  • Revenue This Year
  • RCUS N/A
  • SDGR $22.63
  • Revenue Next Year
  • RCUS N/A
  • SDGR $19.77
  • P/E Ratio
  • RCUS N/A
  • SDGR N/A
  • Revenue Growth
  • RCUS 6.07
  • SDGR 18.59
  • 52 Week Low
  • RCUS $6.50
  • SDGR $16.60
  • 52 Week High
  • RCUS $18.98
  • SDGR $28.47
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 68.53
  • SDGR 51.94
  • Support Level
  • RCUS $12.89
  • SDGR $20.44
  • Resistance Level
  • RCUS $16.12
  • SDGR $22.03
  • Average True Range (ATR)
  • RCUS 0.73
  • SDGR 0.94
  • MACD
  • RCUS 0.07
  • SDGR 0.18
  • Stochastic Oscillator
  • RCUS 44.17
  • SDGR 47.45

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Share on Social Networks: